Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin

Author(s): Adriana G. Bakalova*, Rossen T. Buyukliev, Rositsa P. Nikolova, Boris L. Shivachev, Rositsa A. Mihaylova, Spiro M. Konstantinov

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 10 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The accidental discovery of Cisplatin’s growth-inhibiting properties a few decades ago led to the resurgence of interest in metal-based chemotherapeutics. A number of well-discussed factors such as severe systemic toxicity and unfavourable physicochemical properties further limit the clinical application of the platinating agents. Great efforts have been undertaken in the development of alternative platinum derivatives with an extended antitumor spectrum and amended toxicity profile as compared to the reference drug cisplatin. The rational design of conventional platinum analogues and the re-evaluation of the empirically derived “structure- activity” relationships allowed for the synthesis of platinum complexes with great diversity in structural characteristics, biochemical stability and antitumor properties.

Methods: The new compounds have been studied by elemental analyses, IR, NMR and mass spectral analyses. The structures of the organic compound and one of the new mixed/ammine Pt(II) complexes were studied by X-ray diffraction analysis. The cytotoxic effects of the compounds were studied vs. the referent antineoplastic agent cisplatin against four human tumour cell lines using the standard MTT-dye reduction assay for cell viability. The most promising complex 3 was investigated for acute toxicity in male and female H-albino-mice models.

Results: A new organic compound (5-methyl-5-(2-thiomethyl)ethyl hydantoin) L bearing both S- and Ncoordinating sites and three novel platinum complexes, 1, 2 and 3 were synthesized and studied. Spectral and structural characterization concluded monodentate S-driven coordination of the ligand L to the metal center in complexes 1 and 2, whereas the same was acted as a bidentate N,S-chelator in complex 3. Ligand L crystallizes in the tetragonal space group I41/a (No 88) with one molecule per asymmetric unit. While complex 3 crystallizes in the monoclinic space group P21/c (No 14) with one molecule per asymmetric unit. In the same complex 3, the platinum ion coordinates an L ligand, a chloride ion and an ammonia molecule. In the in vitro experiments, the tested L and complexes 1 and 2 exhibited negligible cytotoxic activity in all tumor models. Accordingly, complex 3 is twice as potent as cisplatin in the HT-29 cells and is at least as active as cisplatin on the MDA-MB-231 breast cancer cell line. In the in vivo toxicity estimation of complex 3 no signs of common toxicity were observed.

Conclusion: The Pt(II)-bidentate complex 3 exhibited significant cytotoxic potential equaling or surpassing that of the reference drug cisplatin in all the tested tumor models. Negligible anticancer activity on the screened tumor types has been shown by the ligand L and its Pt(II) and Pt(IV) complexes 1 and 2, respectively. Our study on the acute toxicity of the most active complex 3 proved it to be non-toxic in mice models.

Keywords: Pt(II) and Pt(IV) complexes, hydantoins, S-containing ligands, X-ray analysis, mixed ammine/amine complexes, cytotoxicity.

Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584.
Bharti, S.K.; Singh, S.K. Recent developments in the field of anticancer metallopharmaceuticals. Int. J. Pharm. Tech. Res., 2009, 1(4), 1406-1420.
Momekov, G.; Bakalova, A.; Karaivanova, M. Novel approaches towards development of non-classical platinum-based antineoplastic agents: Design of platinum complexes characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr. Med. Chem., 2005, 12(19), 2177-2191.
Brabec, V.; Kasparkova, J. Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat., 2005, 8(3), 131-146.
Rabik, C.A.; Dolan, M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 2007, 33(1), 9-23.
Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int., 2008, 73(9), 994-1007.
Abu-Surrah, A.S.; Kettunen, M. Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin. Curr. Med. Chem., 2006, 13(11), 1337-1357.
Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15), 1869-1883.
Wang, X.; Guo, Z. The role of sulfur in platinum anticancer chemotherapy. Anticancer. Agents Med. Chem., 2007, 7, 19-34.
Pasini, A.; Perego, P.; Balconi, M.; Lupatini, M. Cisplatin analogues with sulfur donor ligands. (Ethylenediamine)Platinum(II) complexes with ligands possessing a sulfinyl or sulfanyl group linked to an anionic oxygen donor atom. Reactivity and cytotoxicity. J. Chem. Soc., Dalton Trans., 1995, 80(4), 579-585.
Chui, W.; Wong, T.; Thenomozhiyal, J. Anticonvulsant activity of phenylmethylene-hydantoins: A structure-activity relation study. J. Med. Chem., 2004, 47, 1527-1535.
Spengler, G.; Evaristo, M.; Handzlik, J.; Serly, J.; Molnár, J.; Viveiros, M.; Kieć-Kononowicz, K.; Amaral, L. Biological activity of hydantoin derivatives on P-Glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Res., 2010, 30(12), 4867-4872.
McKeage, M.J.; Higgins, J.D.; Kelland, L.R. Platinum and other metal coordination compounds in cancer chemotherapy. Br. J. Cancer, 1991, 64(4), 788-792.
Fern, J.; Gil, P.; Iturrino, L.; Matesanz, E.; Meert, T.F.; Megens, A.; Sipido, V.K. Synthesis and structure - activity relationship of 2-(Aminoalkyl)-3,3a,8,12b-tetrahydro-2H- dibenzocyclohepta[1,2-b]furan derivatives: A novel series of 5-HT(2A/2C) receptor antagonists. Bioorg. Med. Chem. Lett., 2004, 14(11), 2765-2771.
Bakalova, A.; Nikolova-Mladenova, B.; Buyukliev, R.; Cherneva, E.; Momekov, G.; Ivanov, D. Synthesis, DFT calculations and characterisation of new mixed Pt(II) complexes with 3-thiolanespiro-5′-hydantoin and 4-thio-1H-tetrahydropyranspiro-5′-hydantoin. Chem. Pap., 2016, 70(1), 93-100.
Bakalova, A.; Buyukliev, R.; Momekov, G. Synthesis, DFT calculations and cytotoxic investigation of platinum complexes with 3-thiolanespiro-5′-hydantoin and 4-thio-1H-tetrahydropyranespiro-5′-hydantoin. J. Mol. Struct., 2015, 1091, 118-124.
Bierbach, U.; Qu, Y.; Hambley, T.W.; Peroutka, J.; Nguyen, H.L.; Doedee, M.; Farrell, N. Synthesis, structure, biological activity, and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3) L] (L = planar nitrogen base). Effect of L and Cis/Trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg. Chem., 1999, 38(15), 3535-3542.
Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A: Found. Crystallogr, 2008, A64, 112-122.
Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65(1-2), 55-63.
Konstantinov, S.M.; Elbl, H.; Berger, M.R. BCR-ABL Influences the antileukaemic efficacy of alkylphosphocholines. Br. J. Haematol., 1999, 107(2), 365-374.
Nakamoto, K. Infrared and Raman Spectra of Inorganic and Coordination Compounds; 6th ed.; A John Wiley & Sons: New Jersey. , 2009.
Michalska, D.; Wysokiński, R. Molecular structure and bonding in platinum-picoline anticancer complex: Density functional study. Collect. Czech. Chem. Commun., 2003, 69, 63-72.
Křikavová, R.; Vančo, J.; Šilha, T.; Marek, J.; Trávníček, Z. Synthesis, characterization, DNA binding studies and in vitro cytotoxicity of platinum(II)-dihalogenido complexes containing bidentate chelating N-donor ligands. J. Coord. Chem., 2016, 69, 2422-2436.
Amharar, Y.; Petit, S.; Sanselme, M.; Cartigny, Y.; Petit, M.; Coquerel, G. Crystal structures, dehydration mechanism, and chiral discrimination in the solid state of a hydantoin derivative. Cryst. Growth Des., 2011, 11, 2453-2462.
Coquerel, G.; Petit, M.N.; Robert, F. Structure of (+)- (S)-5-phenyl-5-ethylhydantoin. Acta Crystallogr. Sect C, 1993, 49(4), 824-825.
Kashif, M.K.; Hussain, A.; Rauf, M.K.; Ebihara, M.; Hameed, S. 5-(4-Fluorophenyl)-5-methylimidazolidine-2,4-Dione. Acta Crystallogr. Sect. E Struct. Rep. Online, 2008, E64, o444.
Martin, T.; Massif, C.; Wermester, N.; Linol, J.; Tisse, S.; Cardinael, P.; Coquerel, G.; Bouillon, J.P. Efficient preparation of enantiomerically pure α-aryl-α- trifluoromethylglycines via auto seeded programmed polythermic preferential crystallization of 5-aryl-5-trifluoromethylhydantoins. Tetrahedron Asymmetry, 2011, 22(1), 12-21.
Sabounchei, S.J.; Shahriary, P.; Gholiee, Y.; Salehzadeh, S.; Khavasi, H.R.; Chehregani, A. Platinum and palladium complexes with 5-methyl-5-(2-pyridyl)-2,4-imidazolidenedione: Synthesis, crystal and molecular structure, theoretical study, and pharmacological investigation. Inorg. Chim. Acta, 2014, 409(PB), 265-275.
Todorov, P.T.; Petrova, R.N.; Naydenova, E.D.; Shivachev, B.L. Structure, conformation and hydrogen bonding of two amino-cycloalkanespiro-5-hydantoins. Cent. Eur. J. Chem., 2009, 7(1), 14-19.
Cruz-Cabeza, A.J.; Schwalbe, C.H. Observed and predicted hydrogen bond motifs in crystal structures of hydantoins, Dihydrouracils and uracils. New J. Chem., 2012, 36(6), 1347.
Sundquist, W.I.; Ahmed, K.J.; Hollis, L.S.; Lippard, S.J. Solvolysis reactions of cis- and trans-diamminedichloroplatinum(II) in dimethyl sulfoxide. Structural characterization and DNA binding of trans-bis(ammine)chloro(DMSO) platinum(1+). Inorg. Chem., 1987, 26(10), 1524-1528.
Trainer, D.L.; Kline, T.; McCabe, F.L.; Faucette, L.F.; Field, J.; Chaikin, M.; Anzano, M.; Rieman, D.; Hoffstein, S.; Li, D.J. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer, 1988, 41(2), 287-296.
Baik, M.H.; Friesner, R.A.; Lippard, S.J. Theoretical study of cisplatin binding to purine bases: Why does cisplatin prefer guanine over adenine? J. Am. Chem. Soc., 2003, 125(46), 14082-14092.
Reedijk, J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev., 1999, 99(9), 2499-2510.
Sheldrick, G.M. A short history of SHELX. Acta Crystallogr. Sect. A: Found. Crystallogr, 2008, A64, 112-122.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 13 February, 2019
Page: [1243 - 1252]
Pages: 10
DOI: 10.2174/1871520619666190214103345
Price: $65

Article Metrics

PDF: 45